Literature DB >> 1353365

Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumour immunotherapy.

Y Nakamura1, Y Tokuda, M Iwasawa, H Tsukamoto, M Kidokoro, N Kobayashi, S Kato, T Mitomi, S Habu, T Nishimura.   

Abstract

A simple method for the rapid expansion of human CD4+ T cells with both helper and killer functions was established. CD4+ T cells separated from peripheral blood mononuclear cells using immunomagnetic beads were stimulated with immobilised OKT-3 monoclonal antibody (mAb) plus recombinant interleukin 2 (rIL-2) in 96 well culture plates. After 6 day-culture, the CD4+ T cells were restimulated by immobilised OKT-3 mAb for an additional 24 h, then inoculated into concentrated rotary-tissue culture bag and cultured for further 9 days. This procedure yielded a 3000-fold increase in cell number (about 3-5 x 10(9) per bag). Most of the cells (over 96%) continued to express CD4+ antigen and retained their capacity to produce IL-2. The activated CD4+ T cells showed marked cytotoxicity against Fc receptor positive tumour cells in the presence of OKT-3 mAb. Moreover, we succeeded in a specific targeting of the expanded CD4+ helper/killer T cells to c-erb B-2 positive tumour cells by means of anti-CD3 x anti-c-erb B-2 bispecific antibody. These results suggested that our established simple system will be available for the expansion of large number of CD4+ helper/killer T cells which may provide an efficient strategy for adoptive tumour immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353365      PMCID: PMC1977880          DOI: 10.1038/bjc.1992.210

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

1.  Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones.

Authors:  M A Bookman; R Swerdlow; L A Matis
Journal:  J Immunol       Date:  1987-11-01       Impact factor: 5.422

2.  Diet and gastric cancer. A case-control study in Belgium.

Authors:  A J Tuyns; R Kaaks; M Haelterman; E Riboli
Journal:  Int J Cancer       Date:  1992-04-22       Impact factor: 7.396

3.  Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells.

Authors:  Y Ohashi; T Takeshita; K Nagata; S Mori; K Sugamura
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

4.  Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells.

Authors:  T Nitta; K Sato; K Okumura; S Ishii
Journal:  J Neurosurg       Date:  1990-03       Impact factor: 5.115

5.  Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2.

Authors:  J Bubeník; J Símová; T Jandlová
Journal:  Immunol Lett       Date:  1990-02       Impact factor: 3.685

6.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer; S Gillis
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

7.  A new compact and cell dense continuous culture system.

Authors:  Y Nakamura; K Watanabe; T Noto; T Tajima; M Yamamura
Journal:  J Immunol Methods       Date:  1989-03-10       Impact factor: 2.303

8.  Thymic stromal cell clone with nursing activity supports the growth and differentiation of murine CD4+8+ thymocytes in vitro.

Authors:  T Nishimura; Y Takeuchi; Y Ichimura; X H Gao; A Akatsuka; N Tamaoki; H Yagita; K Okumura; S Habu
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

9.  Macrophage-T cell interaction is essential for the induction of p75 interleukin 2 (IL-2) receptor and IL-2 responsiveness in human CD4+ T cells.

Authors:  Y Nakamura; T Nishimura; Y Tokuda; N Kobayashi; K Watanabe; T Noto; T Mitomi; K Sugamura; S Habu
Journal:  Jpn J Cancer Res       Date:  1991-03

10.  Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.

Authors:  T Nishimura; Y Nakamura; Y Takeuchi; X H Gao; Y Tokuda; K Okumura; S Habu
Journal:  Jpn J Cancer Res       Date:  1991-11
View more
  3 in total

1.  Adoptive tumour immunotherapy using human CD4+ T-cells.

Authors:  J E Gold; M E Osband
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

2.  Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.

Authors:  Ulka Vaishampayan; Archana Thakur; Ritesh Rathore; Nicola Kouttab; Lawrence G Lum
Journal:  Prostate Cancer       Date:  2015-02-23

3.  Expression of tumor-associated glycoantigen, sialyl Lewis(a), in human head and neck squamous cell carcinoma and its application to tumor immunotherapy.

Authors:  K Makino; T Ogata; H Miyake; S Habu; T Nishimura
Journal:  Jpn J Cancer Res       Date:  1994-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.